首页> 外文会议>Annual Convention of the American Association of Equine Practitioners >Orally Administered Sub-Antimicrobial Doxycycline Attains Synovial Fluid Levels Capable of Inhibiting Matrix Metalloproteinases 3 and 13
【24h】

Orally Administered Sub-Antimicrobial Doxycycline Attains Synovial Fluid Levels Capable of Inhibiting Matrix Metalloproteinases 3 and 13

机译:口服施用的亚抗菌毒素患者达到能够抑制基质金属蛋白酶3和13的滑膜液水平

获取原文

摘要

This study confirms that intragastric administration of low-dose doxycycline results in measurable synovial-fluid doxycycline concentrations; this may decrease cartilage catabolism through inhibition of matrix metalloproteinases and may slow the progression of osteoarthritis. Tetracyclines have been used to alleviate symptoms and slow the progression of osteoarthritis (OA). In vitro studies indicate that doxycycline at concentrations of 0.0462 (jig/ml significantly decreases matrix metalloproteinases(MMPs) 3 and MMP-13 gene expression in synoviocytes treated with either inter-leukin-1 or MMP-13. The purpose of this study was to determine if low-dose doxycyclinea administered orally could achieve anti-MMP concentrations in synovia! fluid and plasma.
机译:本研究证实,胃内施用低剂量毒素导致可测量的滑膜液体胞嘧啶浓度;这可能通过抑制基质金属蛋白酶来减少软骨分解代谢,并且可能减缓骨关节炎的进展。四环素已被用来缓解症状并减缓骨关节炎的进展(OA)。体外研究表明,在用Leukin-1或MMP-13或MMP-13治疗的Synoviocytes中,浓度为0.0462(Jig / ml的浓度为0.0462(Jig / ml)的强力环素(夹具金属蛋白酶(MMPS金属蛋白酶(MMP)3和MMP-13基因表达。本研究的目的是确定口服施用低剂量的Doxycyclinea是否可以在Symovia中达到抗MMP浓度!液体和血浆。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号